

Oncology Today with Dr Neil Love: Role of HER2-Directed Therapy in the Treatment of HER2-Expressing Gastrointestinal Cancers — Part 2 of a Special 3-Part Edition

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

1. Which of the following cancer types has the highest rate of HER2 positivity?
 - a. Colorectal adenocarcinoma
 - b. Intrahepatic biliary tract cancer
 - c. Extrahepatic biliary tract cancer
 - d. Gallbladder cancer
2. Which dose of trastuzumab deruxtecan (T-DXd) exhibited the higher overall response rate for patients with HER2-amplified or HER2-overexpressing metastatic colorectal cancer in the Phase II DESTINY-CRC02 study?
 - a. 5.4 mg/kg every 3 weeks
 - b. 6.4 mg/kg every 3 weeks
 - c. Overall response rates were equivalent between the 2 doses
3. Which of the following drug types best describes the mechanism of action of zanidatamab?
 - a. Anti-PD-1/PD-L1 antibody
 - b. HER2-targeting bispecific antibody
 - c. Claudin 18.2-targeting monoclonal antibody
 - d. TROP2-directed antibody-drug conjugate
4. In a recent Phase II basket trial evaluating the combination of tucatinib and trastuzumab, what was the approximate confirmed objective response rate for patients with HER2-positive metastatic biliary tract cancer?
 - a. 15%
 - b. 30%
 - c. 50%
5. Clinical trial data suggest that which of the following adverse events is most common among patients receiving zanidatamab for HER2-positive metastatic biliary tract cancer in the HERIZON-BTC-01 study?
 - a. Diarrhea
 - b. Dry mouth
 - c. Infections
 - d. Interstitial lung disease